JAK2 and neoplasm: Cellular experiments have confirmed that in JAK2V617F-mutant cells, STAT3/5 phosphorylation, driven by oncogenic JAK2 activity, enhances PD-L1 promoter activity and PD-L1 protein expression, which inhibits T cell activity [36], downregulates antitumor immunity, and promotes tumor invasion.